Annual report 2022

— Compensation report — Compensation of the Board of Directors for 2022

Compensation of the Board of Directors for 2022

The following table discloses the compensation paid to the members of the Board of Directors for financial year 2022 while performing services for medmix:

 

 

2022

thousands of CHF

 

Cash fees

 

Restricted share unit (RSU) plan 4)

 

Social security contributions 5)

 

Total

Greg Poux-Guillaume, Chairman 1)

 

150

 

150

 

23

 

323

Barbara Angehrn 2)

 

49

 

65

 

9

 

123

Daniel O. Flammer 2)

 

49

 

65

 

9

 

123

Rob ten Hoedt 2)

 

54

 

73

 

10

 

137

David Metzger 2)

 

45

 

60

 

8

 

113

Marco Musetti 1)

 

74

 

73

 

12

 

159

René Willi 2)

 

49

 

65

 

9

 

123

Jill Lee 3)

 

19

 

0

 

2

 

21

Board of Directors

 

489

 

551

 

82

 

1’122

 

 

2021

thousands of CHF

 

Cash fees

 

Restricted share unit (RSU) plan 4)

 

Social security contributions 5)

 

Total

Greg Poux-Guillaume, Chairman

 

42

 

79

 

12

 

133

Jill Lee

 

22

 

41

 

6

 

69

Marco Musetti

 

22

 

41

 

4

 

67

Board of Directors

 

86

 

161

 

22

 

269

1) Member of the Board of Directors since September 20, 2021.

2) Member of the Board of Directors since April 12, 2022.

3) Member of the Board of Directors from September 20, 2021 to April 12, 2022.

4) RSU awards granted in 2022 had a fair value of CHF 32.7472 at grant date. The amount represents the full fair value of grants made in 2022.

5) The amount includes mandatory social security contributions on the cash fees and estimated contributions on the RSU (based on their fair value at grant) paid by the company on behalf of the Board members.

As of December 31, 2022, there were no outstanding loans or credits granted to the members of the Board of Directors, former members of the Board of Directors or related parties. In 2022, no compensation was granted to former members of the Board of Directors or related parties.

Reconciliation between the reported board compensation and the amount approved by the shareholders at AGM

At the AGM 2022, shareholders approved a maximum aggregate compensation amount of CHF 1,500,000 for the Board of Directors for the period of office from the 2022 AGM until the end of the 2023 AGM. The table below shows the reconciliation between the compensation that was/will be paid out for the periods of office and the maximum aggregate compensation amounts approved by the shareholders.

thousands of CHF

 

Compensation earned during financial year as reported (A)

 

Less compensation earned from Jan to AGM of financial year (B)

 

Plus compensation accrued from Jan to AGM of year following financial year (C)

 

Total compensation earned for the period from AGM to AGM of medmix (A-B+C)

 

Amount approved by shareholders at respective AGM

 

Ratio between compensation earned for the period from AGM to AGM versus amount approved by shareholders

2022 AGM - 2023 AGM

 

2022

 

January 1, 2022 to 2022 AGM medmix

 

January 1, 2023 to 2023 AGM medmix

 

2022 AGM to 2023 AGM

 

2022 AGM

 

2022 AGM

Board of Directors Total

 

1’122

 

82

 

148

148

1’188

 

1’500

 

79.2%

 

 

Compensation earned during financial year as reported from the EGM of Sulzer till the end of year (A)

 

Less compensation earned from Jan to AGM of financial year (B)

 

Plus compensation accrued from Jan to AGM of medmix of year following financial year (B)

 

Total compensation earned for the period from EGM of Sulzer to AGM of medmix (A+B)

 

Amount approved by shareholders at respective EGM

 

Ratio between compensation earned for the period from EGM to AGM versus amount approved by shareholders

2021 EGM - 2022 AGM

 

September 20, 2021 to December 31, 2021

 

September 20, 2021 to 2021 EGM

 

January 1, 2022 to 2022 AGM medmix

 

2021 EGM to 2022 AGM

 

2021 EGM

 

2021 EGM

Board of Directors Total

 

269

 

0

 

83

148

352

 

450

 

78.2%